Appendix

Relevant publications

  1. Tibor Bakacs, Konstantin Chumakov. (2024). A Harmless Avian Vaccine Virus Could Be Developed into an Off-the-Shelf “Antibiotic” for Viruses. Qeios. doi:10.32388/AZ4JZV.2.
  2. Bakacs T, Fehér LZ, Puskás LG: Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral Diseases. Qeios. 2024. 10.32388/S7SMJS.2
  3. Bakacs, T., Sandig, V., and Kovesdi, I. (2023). Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and Acyclovir. Pharmaceuticals 16, 226.
  4. Bakacs, T., Chumakov, K., Safadi, R., and Kovesdi, I. (2022a). Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections. Front. Immunol. 13, 1046851. 10.3389/fimmu.2022.1046851.
  5. Bakacs, T., Volker, S., and Kovesdi, I. (2022d). An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARSCoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination. Cureus 14, e28467. 10.7759/cureus.28467.
  6. Bakacs, T., Safadi, R., Puskas, L.G., Feher, L.Z., and Kovesdi, I. (2022b). Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality. Cureus 14, e22750. 10.7759/cureus.22750.
  7. Bakacs, T., Sandig, V., Slavin, S., Gumrukcu, S., Hardy, W.D., Renz, W., and Kovesdi, I. (2022c). A clinically validated, broadly active, oral viral superinfection therapy could mitigate symptoms in early-stage COVID-19 patients. Infect Disord Drug Targets. 10.2174/1871526522666220419130403.
  8. Bakacs T (December 09, 2021) Healing of Severe Herpes Zoster Ophthalmicus Within a Few Days: An Autobiographical Case Report. Cureus 13(12): e20303. doi:10.7759/cureus.20303
  9. Kovesdi, I.R., M.V.; Chumakov, P.M.; Sandig, V.; Bakacs, T. 2020. The Clinically Validated Viral Superinfection Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections. Preprints.
  10. Kleef, R., Nagy, R., Baierl, A., Bacher, V., Bojar, H., McKee, D.L., Moss, R., Thoennissen, N.H., Szasz, M., Bakacs, T. 2020. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution. Cancer Immunol Immunother.
  11. Kovesdi, I., Bakacs, T. 2019. Therapeutic exploitation of viral interference. Infectious Disorders – Drug Targets 19, 1.
  12. Bakacs T, Safadi R, Kovesdi I. Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs. Hepatology, Medicine and Policy. 2018;3(1):2
  13. Hornyak A, Lipinski KS, Bakonyi T, Forgach P, Horvath E, Farsang A et al. Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies. J Gene Med 2015 April 30;17(6-7):116-31.
  14. Mehrishi JN., Bakács T.: HIV and hepatitis G virus/GB virus C co-infection: beneficial or not? THE LANCET Infectious Diseases 5(8) 464-465, 2005.
  15. Bakacs T, Mehrishi JN. Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus. Vaccine 2004;23(1):3-13.
  16. Bakacs T, Mehrishi JN. Intentional coinfection of patients with HCV infection using avian infection bursal disease virus. Hepatology 2002;36(1):255.
  17. Csatary LK, Bakacs T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 1999;281(17):1588-9.
  18. Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res. 1999;19(1B):635-8.
  19. Csatary LK, Schnabel R, Bakács T: Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Anticancer Res. 1999, 19:629-33.
  20. Csatary LK, Telegdy L, Gergely P, Bodey B, Bakacs T. Preliminary report of a controlled trial of MTH-68/B virus vaccine treatment in acute B and C hepatitis: a phase II study. Anticancer Res. 1998;18(2B):1279-82.
LEARN MORE